Literature DB >> 21768800

Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD.

Felipe Filardi da Rocha1, Humberto Correa.   

Abstract

The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present report, we describe an adult male patient with clomipramine treatment-resistant OCD who did not respond to augmentation with risperidone and aripiprazole but who showed clinical improvement with agomelatine. The effect of agomelatine in resynchronizing circadian rhythms may demonstrate the importance of the circadian rhythm disruption observed in OCD. Moreover, the regulation of the serotoninergic system is circadian in nature, and the resynchronization of the serotoninergic system may regulate serotoninergic dysfunction, a major factor in OCD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768800     DOI: 10.1097/WNF.0b013e318223421f

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  5 in total

Review 1.  Circadian rhythms in obsessive-compulsive disorder.

Authors:  Klaus W Lange; Katharina M Lange; Joachim Hauser; Lara Tucha; Oliver Tucha
Journal:  J Neural Transm (Vienna)       Date:  2012-04-28       Impact factor: 3.575

Review 2.  Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.

Authors:  Domenico De Berardis; Michele Fornaro; Nicola Serroni; Daniela Campanella; Gabriella Rapini; Luigi Olivieri; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Andrea De Bartolomeis; Alessandro Valchera; Giampaolo Perna; Monica Mazza; Marco Di Nicola; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

3.  Venlafaxine augmentation with agomelatine in a patient with obsessive-compulsive disorder and suicidal behaviors.

Authors:  Maria S Signorelli; Carmen Concerto; Eliana Battaglia; Maria C Costanzo; Fortunato Battaglia; Eugenio Aguglia
Journal:  SAGE Open Med Case Rep       Date:  2014-12-04

Review 4.  What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?

Authors:  Petr Potměšil
Journal:  Ther Adv Psychopharmacol       Date:  2019-07-07

5.  Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report.

Authors:  Domenico De Berardis; Nicola Serroni; Stefano Marini; Giovanni Martinotti; Francesca Ferri; Gaetano Callista; Raffaella La Rovere; Francesco Saverio Moschetta; Massimo Di Giannantonio
Journal:  Case Rep Psychiatry       Date:  2012-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.